Hi [[ session.user.profile.firstName ]]

WIPR and BSKB present: Obviousness in PTAB Trials for Chem/Pharma/Bio Patents

Challenging patents involving unpredictable technologies for obviousness is particularly difficult due to the well-established factor of “reasonable expectation of success” and the related KSR factor of “limited number of predictable solutions”. This webinar, presented by attorneys that have successfully argued on both sides of this issue for chem/pharma/bio patents, will discuss two to three leading PTAB decisions, including related appeals, that illustrate when obviousness challenges have and have not been successful. The case discussions will provide (1) a summary of the documentary evidence relied on, including critical excerpts from that evidence, (2) a summary of the “story” that was being told by each party and (3) the role that expert testimony appeared to play in the PTAB decisions. This one-hour seminar will also briefly explore what types of cases are better challenged in court and what types of cases are better challenged at the PTAB. The goals of the seminar are to allow parties to evaluate the chances of success for a contemplated or recently filed PTAB challenge and to help parties to a PTAB proceeding develop a record to support their respective positions. CLE available.
Recorded Oct 13 2016 66 mins
Your place is confirmed,
we'll send you email reminders
Presented by
Gerald Murphy (BSKB), Eugene Perez (BSKB), Kristi Sawert (USPTO), Peter Scott (WIPR)
Presentation preview: WIPR and BSKB present: Obviousness in PTAB Trials for Chem/Pharma/Bio Patents
  • Channel
  • Channel profile
  • Patenting computer-implemented healthcare inventions in AI and machine learning Apr 23 2020 2:00 pm UTC 75 mins
    Dr Andrew McGettrick (HGF), Peter Scott (WIPR)
    The European Patent Office (EPO) has recognised the importance of artificial intelligence (AI) and machine learning by updating the EPO Guidelines for Examination to focus on the patentability of innovations having an AI aspect. The EPO held a conference in 2018 directed to patenting AI, testament to the impact AI is having in all areas of technology.
    It is a common misconception that computer software cannot be patented. Although not all software is patentable, software in the medical technology field is often patentable. Navigating exclusions to patentability can be a challenge with AI inventions because they can be viewed as a form of mathematical method, which are on the list of non-inventions defined by the European Patent Convention.
    Although routine implementation of AI or machine learning to solve a problem foreseeably solvable by AI is unlikely to be sufficient to obtain patent protection, it is eminently possible to obtain patent protection for AI inventions.
    This webinar will explore by example how to approach the patenting of AI inventions in the medical field and how to navigate the exclusions from patentability, including some types of computer software, pure mathematical methods and methods of diagnosis.
  • Key Considerations for a FRAND Patent Licensing Strategy - Panel Discussion Recorded: Mar 12 2020 49 mins
    Ryan Richardson (Sterne Kessler), Hongming Liu (Tencent America), Ken Seddon (The LOT Network), Andrew Schwaab (SVIPLA)
    Preceded by an introduction to The LOT Network by, CEO, Ken Seddon.

    This webinar was originally programmed as a panel discussion/presentation at Technology Patent Network North America in San Jose on March 12. In light of the continuing COVID-19 outbreak, we have postponed that event to a date to be confirmed later in 2020. In the meantime, we hope you enjoy these presentations and that you'll join us when the revised conference programme is delivered in person. All registrations for the San Jose event will be valid for the rescheduled event.
  • Patenting Artificial Intelligence: Use of Patents or Trade Secrets Recorded: Mar 12 2020 31 mins
    David Sanker, Partner, Morgan Lewis & Bockius
    Patenting Artificial Intelligence: Use of Patents or Trade Secrets

    As Innovation is now Outpacing the Law, is it Time to Devise a Broader Legal Strategy to Protect IP in AI?
    How do you Develop a Trade Secrets Strategy?

    This webinar was originally programmed as a presentation at Technology Patent Network North America in San Jose on March 12. In light of the continuing COVID-19 outbreak, we have postponed that event to a date to be confirmed later in 2020. In the meantime, we hope you enjoy these presentations and that you'll join us when the revised conference programme is delivered in person. All registrations for the San Jose event will be valid for the rescheduled event.
  • Best Practice for In-House IP Counsel: Invention Harvesting - Panel Discussion Recorded: Mar 12 2020 45 mins
    Jennifer Lane Spaith (Dorsey & Whitney), Mehul Shah (Nagra/Kudelski), Peter Jovanovic (Dell)
    This webinar was originally programmed as a panel discussion at Technology Patent Network North America in San Jose on March 12. In light of the continuing COVID-19 outbreak, we have postponed that event to a date to be confirmed later in 2020. In the meantime, we hope you enjoy these presentations and that you'll join us when the revised conference programme is delivered in person. All registrations for the San Jose event will be valid for the rescheduled event.
  • Patenting Artificial Intelligence Recorded: Feb 11 2020 58 mins
    Peter Scott (WIPR), Dr Susan Keston (HGF), Jeff Clarke (HGF)
    As patent attorneys we are trained to tease out the thoughts of a human inventor in tackling a problem. However, inventions involving artificial intelligence (AI) can present us with the challenge of an inventor explaining that with sufficient input data, the “black box” number-crunching outputs a neat solution to the problem posed.

    We are not yet at a point at which AI-powered machines and software have become untethered from the supervision of human beings. However, if you use Apple’s Siri, you are benefiting from AI-based natural language processing. Google’s DeepMind is applying AI to process raw data from the environment to emulate human learning, and AI-driven software can predict epileptic seizures with incredible accuracy.

    This webinar explores invention-spotting strategies for AI innovations. The aftermath of the US Supreme Court’s Alice decision can lead to some AI innovations being categorised as patent-ineligible “abstract ideas”. However, the European Patent Office (EPO) has a stable and long-established body of case law in the assessment of computer-implemented inventions via the problem-solution approach.

    We believe that the European approach can be helpful in navigating patent eligibility arguments in the US. We shall review useful practical examples from EPO case law of attempts to protect AI inventions.
  • The CRISPR IP Saga - the latest chapter and looking to the next Recorded: Oct 10 2019 67 mins
    Dr Claire Irvine (Partner, HGF), Douglas Drysdale (Partner, HGF)
    CRISPR gene-editing continues to hit the headlines regularly as a ground-breaking technology with many millions now flowing into companies seeking to exploit the technology in both the therapeutic and agricultural fields. Unfortunately, the IP landscape continues to lack clarity with possibility of divergence between Europe and the US.

    This webinar will provide an update on the CRISPR IP saga and seek to shine light on the interplay between the latest chapter in the US, starting with new interference proceedings instigated by the USPTO, and opposition and appeal proceedings affecting key European patents at the European Patent Office. With oral proceeding now scheduled for early February 2020 for the opposition to the basic European patent of the University of California et al. and availability of a non-binding preliminary opinion on the arguments from the opposition board, it is an apt time for review of the main focus of the battle - coverage of CRISPR/Cas9 gene-editing in eukaryotic cells. The webinar will also discuss the considerations for those needing to think about freedom-to–operate in the absence of resolution of a standard for CRISPR gene-editing for therapy and the growing number of
    claims outside the main battle lines.

    This webinar is aimed at those wishing to hear about the latest developments in the CRISPR IP landscape whether in the commercial, academic, legal or patent world. With the CRISPR IP saga not evidently close to the final chapter, it will also provide an opportunity to raise questions which may arise from the on–going lack of clarity.
  • Blockchain: Using technology to protect copyright in a new age Recorded: Sep 10 2019 57 mins
    Jeferson Staelens (Orbit Seed), Alessia Parassina (Brandstock), Peter Scott (WIPR)
    WIPR and Brandstock are hosting a complimentary webinar on the exciting possibilities blockchain offers copyright owners.
    Our expert speakers will guide listeners through the latest blockchain developments, including the security of blockchain tools, the value of blockchain-stamped evidence, and the improvements it can make to licence agreements—plus much more.
  • CAR-T and other immunotherapies Recorded: Sep 3 2019 62 mins
    Iain Armstrong (Partner, HGF), Peter Scott (Editor-in-Chief, LSIPR)
    Immunotherapies, such as CAR-T cells, are a hugely promising therapeutic area, both in terms of clinical benefits and potential market size.
    While the treatments are complicated and expensive, they have proven remarkably effective in achieving positive outcomes in forms of cancer that are otherwise difficult to treat. As a result, their clinical use has recently been approved in both the US and Europe.
    The webinar will consider how commercial and technological developments have also impacted patent filings in this area. As the field becomes increasingly crowded, the likelihood of obtaining very broad patent protection decreases. However, the number of patent filings continues to grow dramatically.
  • Best Practice for In-House IP Counsel: Invention Harvesting Recorded: Jun 11 2019 75 mins
    Matt Cassie, Patent Attorney, HGF
    This webinar will provide an overview of the activities, organisational structures and business processes that can be designed and implemented to build an effective IP harvesting system according to the needs of different enterprises. From this, listeners will learn about best practice in this aspect of IP management which will empower them to build from scratch or improve existing Invention Harvesting processes.
  • Maximising the efficiency of your IP portfolio Recorded: May 7 2019 51 mins
    Peter Scott (WIPR), Federico Rizzo (Diadora), Alessia Parassina (Brandstock)
    In this webinar, we'll discuss the best approaches to IP portfolio management, hearing from industry on what they consider best practice and looking at potential solutions to help you manage your portfolio effectively.

    As IP rights increase in importance to businesses, so do the threats to them, the costs of maintaining them, and the complexity of making good decisions about how to direct and manage them. This webinar will help you understand what strategies are available, and how to ensure that portfolio management is resource and cost-effective in your organisation.
  • Update on The CRISPR IP Saga - Still Far from The Final Chapter Recorded: Mar 12 2019 65 mins
    Dr Claire Irvine (HGF Ltd), Sarah Morgan (Life Sciences IP Review)
    CRISPR gene-editing continues to hit the headlines regularly as a ground-breaking technology with many millions now flowing into companies seeking to exploit the technology in both the therapeutic and agricultural fields. Unfortunately, the IP landscape continues to lack clarity with possibility of divergence between Europe and the US.

    This webinar is aimed at those wishing to hear about the latest developments in the CRISPR IP landscape whether in the commercial, academic, legal or patent world. With the CRISPR IP saga seemingly not close to the final chapter, it will also provide an opportunity to raise questions which may arise from the on–going lack of clarity.
  • Actavis and equivalence – where are we now? Recorded: Oct 11 2018 63 mins
    Douglas Drysdale, partner, HGF
    The UK Supreme Court's 2017 decision in Actavis v Eli Lilly introduced a doctrine of equivalents into UK law. In this webinar, we'll discuss the implications of that decision and look at how it is being applied in other cases in the UK courts.
  • Second Medical Use Patent Opportunities from Personalised Healthcare Inventions Recorded: Sep 11 2018 58 mins
    Dr. Laurence Gainey, Patent Director, HGF
    Personalised healthcare (sometimes referred to as precision medicine) is an evolving field in medicine where a therapeutic treatment is tailored to an individual with a particular disease. The patenting of personalised healthcare inventions has proved problematic in a number of jurisdictions, most notably the USA. However, various aspects of these inventions are patentable in Europe.

    This webinar will set the scene as to what personalised healthcare is and will run through the history of second medical use patenting in Europe. Discussing key cases such as G5/83, T1020/03 and G2/08.

    It will then focus on how second medical use patenting can be applied to personalised healthcare inventions and will give examples of claim language that is finding favour at the EPO.
  • CRISPR: Updates and trends in opposition and appeal practice before the EPO Recorded: Mar 21 2018 42 mins
    Catherine Coombes (HGF), Dr. Chris Moore (HGF), Peter Scott (WIPR)
    This webinar will be on opposition and appeals practice before the EPO. We’ll be discussing the streamlining of the opposition procedure by the EPO, the changes that we are seeing as a result and will be providing practical tips in view of these changes. The talk will also draw on recent case law.
  • Protecting the Pot of Gold: Patent Applications for Therapeutic Antibodies Recorded: Jan 30 2018 63 mins
    Gerald Murphy (BSKB), John Heithaus (BSKB), Peter Scott (WIPR)
    Over the last 10 years, multiple patents on therapeutic antibodies have been invalidated in the courts, often for lack of written description. Many other cases are working their way through the courts and the PTAB. This webinar will review major CAFC and PTAB decisions affecting therapeutic antibodies and will explore the best ways to obtain valuable and enforceable patents on therapeutic antibodies. The main issues to be covered are Section 101 issues (laws of nature, natural phenomena and natural products), obviousness and written description.
  • Saving money immediately on your IP assets: Auditing your trademark portfolio Recorded: Oct 26 2017 58 mins
    Guido Chiavelli (CEO, Il Gufo), Alessia Parassina (Lawyer, Brandstock), Angela La Marca (IP counsel) Ed Conlon (WIPR),
    With the year approaching its end, many IP departments will be looking at how best to rationalise their work for 2018. This webinar explores how to ensure your trademark portfolio is in the best possible shape using a two part verification and audit process to save you time and money on your IP assets, as well as analyzing your current and planned costs and guiding your filing strategy in the new year.
  • WIPR and RWS IP Services present: 10 Steps for Managing Your Patents in China Recorded: Oct 17 2017 42 mins
    Caroline Chenique (Global Director of Sales & Marketing, RWS), Justin Simpson (RWS, founder of inovia) and Ed Conlon (WIPR)
    Join WIPR and RWS IP Services for a complimentary webinar as we discuss patent filing strategies in China.

    As the largest growing consumer market in the world, enforcing your intellectual property (IP) in China has become increasingly critical. In this webinar, we will discuss the ten steps your organization should take when seeking patent protection and help you formulate your commercial IP strategy.
  • WIPR and HGF present: Biotech patentability issues in Europe Recorded: Sep 27 2017 58 mins
    Iain Armstrong (Partner, HGF), Dr. Laurence Gainey (Patent Director, HGF) and Peter Scott (Publisher, WIPR/LSIPR)
    This webinar will cover the current state of play in Europe regarding biotech patentability issues, including recent case law on what data you need to make an invention in this area plausible. It will also look at how recent rule changes have influenced patentability of plants and animals before the EPO. Finally, we will compare patentability practice in different jurisdictions around the world, most notably in the US, China and Japan.
  • The jungle of IP ownership: How to manage your IP Recordals Recorded: Jun 27 2017 59 mins
    Anna Popova (Brandstock), Ingo Dauer (L'Occitane en Provence), Sandra Hammelmann (Abbott), Peter Scott (WIPR)
    WIPR and Brandstock present this one hour webinar looking at IP recordals projects and the challenges brands face when undertaking this kind of work.
  • WIPR and BSKB present: The Halo effect: walking the willfulness tightrope Recorded: May 16 2017 57 mins
    Peter Scott (WIPR), Michael Mutter (BSKB), Shawn Hamidinia (BSKB)
    The US Supreme Court's recent decision in Halo Electronics, Inc. v. Pulse Electronics, Inc has big implications.

    This one-hour webinar will briefly address the history of willful infringement and the obligations to avoid infringement before and after the Seagate decision and as changed by Halo.

    It will also focus on how to best establish good faith with a non-infringement/invalidity position post-Halo including where a product was introduced post-Seagate and prior to Halo.
Providing insight on Intellectual Property and the Life Sciences
Content for the home of World IP Review and Life Sciences IP Review

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: WIPR and BSKB present: Obviousness in PTAB Trials for Chem/Pharma/Bio Patents
  • Live at: Oct 13 2016 3:30 pm
  • Presented by: Gerald Murphy (BSKB), Eugene Perez (BSKB), Kristi Sawert (USPTO), Peter Scott (WIPR)
  • From:
Your email has been sent.
or close